Sector News

Endo’s restructuring underway

November 9, 2016
Life sciences

Endo’s move to trim manufacturing operations in the U.S. as part of a companywide restructuring plan has begun amid reports it has found a buyer for its Charlotte, NC, facility which the company had planned to close and let go of up to 300 employees.

The Dublin, Ireland-based company has found a buyer for the facility, which is operated by its Qualitest subsidiary, in-Pharma Technologist reported, citing an unnamed company spokeswoman. Details of the deal weren’t disclosed.

“We’ve actually entered into a formal agreement to sell the facility, signed earlier this week and, as part of the agreement, the new buyer has committed to retain 125 current employees,” the spokeswoman said.

Last week, Endo filed a WARN Act notice with the North Carolina Department of Commerce that said it planned to let go of 282 workers at the plant by the end of the year.

A similar WARN Act notice has yet to be filed in Alabama, where Endo previously said it will eliminate about 350 of the estimated 1,248 employees located at the plant.

The 88,000-square-foot Charlotte manufacturing operation produces tablets and capsules of generic drugs.

The layoffs and closure of the Charlotte plant are part of Endo’s response to revenue losses attributed to tighter competition in the generics market and delays on regulatory action for some of its products, the company said earlier this year.

With the restructuring, Endo hopes to save $60 million in 2017. The moves in the U.S. are mostly focused on Endo’s Qualitest operations, which the company acquired for $1.2 billion in 2010.

Editor’s Note: The story was updated to reflect a report that Endo had found an undisclosed buyer for the Charlotte, NC, plant.

By Joseph Keenan

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.